There are retrospective data (i.e. PMID 15072456) that seem to associate posterior fossa location with increased risk of leptomeningeal disease after surgery. Do you feel that this is a true association and does it impact your treatment recommendations? Also, if a patient has surgery for posterior fossa metastasis are you more apt to offer WBRT versus SRS boost considering this risk, and would you ever treat the posterior fossa alone?